8-KMaterial AgreementsFinancial EventsExhibits & Filings

CME GROUP INC. 8-K Report, Material Agreement (Sep 9, 2013)

Filed September 9, 2013For Securities:CME

Summary

CME Group Inc. (CME) filed an 8-K on September 9, 2013, to report the completion of a public offering of $750 million in 5.300% Notes due 2043. This offering was conducted under a shelf registration statement and was supplemented by a prospectus dated September 4, 2013. The primary stated purpose of this debt issuance is to refinance CME's outstanding 5.75% notes which are due to mature in February 2014. This debt refinancing demonstrates prudent financial management by CME Group, aiming to replace higher-cost debt with lower-cost debt, thereby potentially improving interest expense and enhancing profitability. The issuance also extends the maturity profile of the company's debt, providing greater financial flexibility. Investors should note the terms of the new notes, including their interest rate, maturity date, and the covenants outlined in the Indenture, which provide certain protections against a change of control or credit rating downgrades.

Key Highlights

  • 1Completion of a $750 million public offering of 5.300% Notes due 2043.
  • 2Primary use of proceeds is to retire outstanding 5.75% notes maturing in February 2014.
  • 3The offering was conducted under an automatic shelf registration statement.
  • 4Entered into an Underwriting Agreement with major financial institutions on September 4, 2013.
  • 5Notes issued under an Indenture, supplemented by a Sixth Supplemental Indenture dated September 9, 2013.
  • 6The effective interest rate on the notes was fixed at approximately 4.73% due to a forward-starting interest rate swap.
  • 7The Indenture includes covenants limiting certain actions and provides for a change of control put option and redemption rights.

Frequently Asked Questions

The primary purpose of the $750 million note issuance is to refinance CME Group's outstanding 5.75% notes that are due to mature in February 2014. This move aims to replace higher-cost debt with lower-cost debt and manage the company's maturity profile.

The new notes have a stated interest rate of 5.300% and mature in 2043. However, due to a forward-starting interest rate swap, the effective fixed interest rate at issuance is estimated to be approximately 4.73%.

The Indenture governing the notes includes covenants that limit certain company actions. Importantly, it contains a provision requiring CME Group to offer to repurchase the notes at 101% of their principal amount, plus accrued interest, if there is a change of control combined with a downgrade of the notes below investment grade by both Moody's and S&P within a specified timeframe.

Yes, CME Group has the option to redeem the notes at any time prior to March 15, 2043, at a redemption price equal to 100% of the principal amount plus a make-whole premium. On or after March 15, 2043, they can redeem the notes at 100% of the principal amount.